Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Home›Research›Companies

Companies

Loading

SynsoryBio

AddedMar 17, 2024

UpdatedJul 7, 2026

SynsoryBio

Seed

SynsoryBio: Crafting smart protein drugs targeting only diseased cells.

Founded

Accelerator

Y Combinator W24

SynsoryBio's mission is to develop next-generation protein therapeutics that activate exclusively in diseased tissues, enhancing the therapeutic window of potent drugs. Their technology aims to revolutionize treatments for diseases like cancer and autoimmune disorders by providing targeted, conditional activation of protein drugs.

SynsoryBio has made significant strides in the biotech industry by advancing its unique platform for smart protein drugs. Their innovative approach has the potential to significantly improve patient outcomes and reduce side effects, positioning them as a leader in targeted therapeutics.

SynsoryBio - Similar Companies

Serna Bio

serna.bio

AI Proteins

aiproteinstx.com

Synkrino Biotherapeutics

synkrino.bio

Engage Bio

Catena Biosciences

Serinus Biosciences

serinus.bio

Eris Biotech

erisbio.com

Synvivia

synvivia.com

Syntis Bio

syntis.bio

ParcelBio

parcelbio.com

Synthekine

synthekine.com

Nabla Bio

nabla.bio

Modulari-T

modularit.bio

Output Biosciences

outputbio.com

Invitris

invitris.com

SynsoryBio - Quick Facts

Who are SynsoryBio's competitors?

Companies similar to SynsoryBio include Serna Bio, AI Proteins, Synkrino Biotherapeutics and Engage Bio.

When was SynsoryBio founded?

SynsoryBio was founded in 2023.

When was SynsoryBio's last funding round?

SynsoryBio's most recent funding round was for $500k (USD) in January 2024.

How much has SynsoryBio raised to-date?

As of Jan 1, 2024, SynsoryBio has raised a total of $500k (USD).

How many employees does SynsoryBio have?

SynsoryBio has 2 employees as of Apr 3, 2024.

SynsoryBio - Classification

Ownership: Venture Capital
Technology: Biotech
Geographic Exposure: Global

Revenue: Recurring
Customer: Enterprise
Main Product: Protein Therapeutics

Tags: Healthtech